Adjuvant Therapy With Agonistic Antibodies to CD134 (OX40) Increases Local Control After Surgical or Radiation Therapy of Cancer in Mice-Reference-Cited by-同舟云学术

Adjuvant Therapy With Agonistic Antibodies to CD134 (OX40) Increases Local Control After Surgical or Radiation Therapy of Cancer in Mice

Published:2010-10 Issue:8 Volume:33 Page:798-809
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Gough Michael J.,Crittenden Marka R.,Sarff MaryClare,Pang Puiyi,Seung Steven K.,Vetto John T.,Hu Hong-Ming,Redmond William L.,Holland John,Weinberg Andrew D.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference56 articles.

1. Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution;Klein;Proc Natl Acad Sci U S A,1977

2. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity;Shankaran;Nature,2001

3. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice;Kaplan;Proc Natl Acad Sci U S A,1998

4. Changing concepts of cancer surgery: surgery as immunotherapy;Morton;Am J Surg,1978

5. Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma?;Hsueh;Annals Surg Oncol,2000

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploiting temporal aspects of cancer immunotherapy;Nature Reviews Cancer;2024-06-17

2. Nano-Pulse Stimulation Treatment Inhibits Pan02 Murine Pancreatic Tumor Growth and Induces a Long-Term Adaptive Immune Response with Abscopal Effects When Combined with Immune-Enhancing Agents;Bioelectricity;2024-06-01

3. Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer;Vaccines;2023-12-07

4. Radiation-targeted immunotherapy: A new perspective in cancer radiotherapy;Cytokine & Growth Factor Reviews;2023-11

5. Challenges and opportunities in the development of combination immunotherapy with OX40 agonists;Expert Opinion on Biological Therapy;2023-08-20